vorinostat has been researched along with Orphan Diseases in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Orphan Diseases: Rare diseases that have not been well studied.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brindisi, M | 1 |
| Saraswati, AP | 1 |
| Brogi, S | 1 |
| Gemma, S | 1 |
| Butini, S | 1 |
| Campiani, G | 1 |
1 other study available for vorinostat and Orphan Diseases
| Article | Year |
|---|---|
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
Topics: Animals; Biomarkers; Cell Line; Epigenesis, Genetic; Histone Deacetylase 6; Histone Deacetylase Inhi | 2020 |